NEW YORK (GenomeWeb) – Officials from Regulus Therapeutics this week provided updates for the company's two lead drug candidates, stating that a Phase I study of its hepatitis C treatment RG-101 is set to yield key data in the next few months, while the preclinical Alport syndrome therapy RG-012 is on track to enter human testing in early 2015.

Separately this week, Regulus announced that it has formed a new collaboration with Biogen Idec to identify microRNA biomarkers for multiple sclerosis (MS). The arrangement builds off of an alliance the companies forged in 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.